Bladder Cancer Detection with EarlyTect® BCD
Hematuria patient and/or risk of bladder cancer. Urine with blood in it.
Linear Target Enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP)
3 – 7 days
Submit with Order
Collecting 20 ml of void urine in 50 ml tube with a preservative provided by Promis DX.
Storage: 2-8°C for up to 7 – 14 days.
1. Unsampled urine specimen in the urine collection container provided by the manufacturer.
2. Specimen with a damaged container or missing label.
3. Specimen stored for more than 7 days after collection.
4. Specimen with a volume of preservative in the collection container below the baseline, where urine was collected.
Ambient: 72 hrs
Refrigerated: 14 days
The EarlyTect® Bladder Cancer (BC) is an proprietary in vitro diagnostic device designed to detect the presence of BC by analyzing urine DNA for patients through qualitative analysis of a single epigenetic biomarker gene DNA methylation (methylated PENK DNA). The EarlyTect® BC is for use with a real-time, methylation-specific PCR detection system coupled with linear target enrichment step after DNA extraction and bisulfite conversion. It detects both methylated PENK and an internal control gene.
Limitation: Improper specimen collection techniques, storage, or shipment protocols may cause unreliable results. An absence of detection does not imply the absence of bladder cancer or does not exclude the possibility that the target sequence is present below the limit of detection. The EarlyTect® BC Report does not take into consideration patient history, drug-drug interactions, drug sensitivity, and/or allergies. It is the responsibility of the physician to determine appropriate drug and dosing choices based on all available data.
Result Interpretation: A positive result indicates the possibility of bladder cancer (BC). A positive result is not confirmatory evidence for bladder cancer. Patients with a positive EarlyTect BC test result should be referred for diagnostic cystoscopy. A negative result indicates lower likelihood of bladder cancer. A negative EarlyTect BC test result does not guarantee absence of cancer. Patients with a negative EarlyTect® test result should be advised to continue participating in a recommended Bladder cancer screening program according to screening guidelines. This test confirmed that patients with hematuria can be diagnosed with 85.7% accuracy for all stages BC and 90% accuracy for TaHG and higher stages BC in clinical trials. At about 10-15% of the level, it can be negative (false negative) on the test, even if it is not negative. In this case, the possibility of a bladder cancer cannot be completely ruled out.